Skip to main content
. 2022 Jun 18;17(3):321–328. doi: 10.1007/s11523-022-00887-w

Table 1.

Characteristics of participating oncologists

Number of physicians (N = 28)
Practice type (n, %)
 Solo practitioner 1 3.6%
 Small private community practice (2–5 physicians) 9 32.1%
 Medium-sized private community practice (6–10 physicians) 6 21.4%
 Large private community practice (> 10 physicians) 5 17.9%
 Community-based hospital owned by an academic center 1 3.6%
 Academic medical center 3 10.7%
 Affiliated teaching hospital 3 10.7%
 VA/military hospital/DoD 0 0.0%
Practice location (n, %)a
 Northeast 7 25.0%
 Midwest 4 14.3%
 South 11 39.3%
 West 6 21.4%
Practice setting (n, %)
 Urban 12 42.9%
 Suburban 10 35.7%
 Rural 6 21.4%
Oncologist years in practice (median, [SD] IQR) 17.0 [6.7] 13-23
Oncologist specialty (n, %)b
 Medical oncology 10 35.7%
 Hematology/oncology 20 71.4%
Number of adult patients with an NTRK+ (with known fusion partner) solid tumor oncologists treated between 01/01/2016-12/31/2019 with at least 3 months of follow-up
Total across all physicians (median [IQR] per physician)c 148 4 (2-8)

DoD Department of Defense, IQR interquartile range, NTRK+ neurotrophic tropomyosin-related kinase gene fusion-positive, SD standard deviation, VA Veterans Affairs

aNortheast (CT, DE, MA, ME, MD, NH, NJ, NY, PA, RI, VT), Midwest (IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, SD, WI), South (AL, AR, DC, FL, GA, KY, LA, MS, NC, OK, SC, TN, TX, VA, WV), West (AK, AZ, CA, CO, HI, ID, MT, NM, NV, OR, UT, WA, WY)

bCategories not mutually exclusive

cOne (1) physician reported 30 patients and was excluded from calculation